Conditions: Hormone-Sensitive Breast Cancer Breast Cancer
Keywords: Neoadjuvant treatment
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 5
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the objective response rate of a combination of letrozole (Femara) and bevacizumab (Avastin) given preoperatively to postmenopausal patients with hormone sensitive breast cancer.

Detailed description:

Arms:
arm 1: brief exposure bevacizumab arm 2: brief exposure bevacizumab and letrozole

Interventions: intervention 1: Letrozole intervention 2: Bevacizumab
Intervention descriptions: intervention 1: Letrozole 2.5 mg po qd intervention 2: bevacizumab 10 mg/kg IV

Protocol document: